美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Lpath

2.94

-0.0701-2.33%

成交量：1.47万

成交额：4.31万

市值：- -

市盈率：- -

高：3.02

开：3.02

低：2.93

收：3.01

52周最高：5.88

52周最低：1.68

股本：- -

流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Lpath

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.lpath.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Lpath, Inc.是一家生物科技公司，专注于脂类基础治疗性抗体的开发与研究，这是一个医疗科学的新兴领域，针对带有生物活性的信号脂质来治疗一系列人类疾病。公司目前有两个候选产品位于临床开发阶段，一个产品位于临床前评估阶段。 Lpath, Inc是发现和开发中和生物活性脂质的单克隆抗体的行业领跑者。脂质研究（称作lipidomics）是一个新兴研究领域，目前已经发现的具有生物活性会促成疾病的有几十个，如果在该领域的资金继续投入的话，还将有数百个相关发现。一旦引起疾病的脂质确定下来接下来的挑战就是生产一种能中和相关生物活性脂质的复合物。通过其免疫Y2平台技术和强大的专利财产，Lpath处在唯一能够面对这些挑战，利用机遇的地位。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/LPTN/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LPTN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LPTN\",,,,,undefined,":{"symbol":"LPTN","market":"US","secType":"STK","nameCN":"Lpath","latestPrice":2.94,"timestamp":1483045200000,"preClose":3.0101,"halted":0,"volume":14706,"delay":0,"changeRate":-0.02328826284841037,"floatShares":0,"shares":0,"eps":0,"marketStatus":"盘后交易","change":-0.0701,"latestTime":"03-25 16:28:32 EDT","open":3.02,"high":3.02,"low":2.93,"amount":43088.58,"amplitude":0.029899,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774483200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.0101,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LPTN\",,,,,undefined,":{"symbol":"LPTN","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":3.02,"amplitude":0.029899,"preClose":3.0101,"low":2.93,"week52Low":1.68,"pbRate":"--","week52High":5.88,"institutionHeld":0,"latestPrice":2.94,"eps":0,"divideRate":0,"volume":14706,"delay":0,"open":3.02,"prevYearClose":16.115},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LPTN\",params:#limit:5,,,undefined,":[{"date":"2016-12-30","symbol":"LPTN","reason":"合并为APEN","type":"delisting","dateTimestamp":1483074000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LPTN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LPTN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.lpath.com","stockEarnings":[{"period":"1week","weight":-0.8176},{"period":"1month","weight":-0.8176},{"period":"3month","weight":-0.8176},{"period":"6month","weight":-0.8176},{"period":"1year","weight":-0.8176},{"period":"ytd","weight":-0.8176}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lpath, Inc.是一家生物科技公司，专注于脂类基础治疗性抗体的开发与研究，这是一个医疗科学的新兴领域，针对带有生物活性的信号脂质来治疗一系列人类疾病。公司目前有两个候选产品位于临床开发阶段，一个产品位于临床前评估阶段。 Lpath, Inc是发现和开发中和生物活性脂质的单克隆抗体的行业领跑者。脂质研究（称作lipidomics）是一个新兴研究领域，目前已经发现的具有生物活性会促成疾病的有几十个，如果在该领域的资金继续投入的话，还将有数百个相关发现。一旦引起疾病的脂质确定下来接下来的挑战就是生产一种能中和相关生物活性脂质的复合物。通过其免疫Y2平台技术和强大的专利财产，Lpath处在唯一能够面对这些挑战，利用机遇的地位。","exchange":"NASDAQ","name":"Lpath","nameEN":"Lpath"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LPTN\",market:\"US\",,,undefined,":null}}